Notification of Intent to Use Schedule III, IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment of Opiate Addiction under 21 USC § 823(g)(2)

Form Approved: 0930-0234 Date: 03/31/2009

See OMB Statement on Reverse

of Opiate Addiction under 21 USC § 823(g)(2)		
	DATE OF SUBMISSION	
Note: Notification is required by § 303(g)(2), Controlled Substances Act (21 USC § 823(g)(2)). See instructions on reverse.		
1a. NAME OF PRACTITIONER		
b. State Medical License Number c. DEA Registration Number		
2. ADDRESS OF PRIMARY LOCATION (Include Zip Code) (See instruction below)	3. TELEPHONE NUMBER (Include Area Code)	
	4. FAX NUMBER (Include Area Code)	
	5. EMAIL ADDRESS (Optional)	
6. PURPOSE OF NOTIFICATION (See instruction below)		
New Notification New Notification, with the intent to immediately facilitate treatment of an individual (one) patient		
7. CERTIFICATION OF USE OF NARCOTIC DRUGS UNDER THIS NOTIFICATION		
I certify that I will only use Schedule III, IV, or V drugs or combinations of drugs that have been approved by the FDA for use in maintenance or detoxification treatment and that have not been the subject of an adverse determination.		
8. CERTIFICATION OF QUALIFYING CRITERIA		
I certify that I meet at least one of the following criteria and am therefore a qualifying physician (Check and provide copies of documentation for all that apply):		
Subspecialty board certification in addiction psychiatry from the American Board of Medical Specialties		
Addiction certification from the American Society of Addiction Medicine		
Subspecialty board certification in addiction medicine from the American Osteopathic Association Completion of not less than eight hours of training for the treatment and management of opioid-dependent patients provided by the following		
organization(s): Date and location of training		
American Society of Addiction Medicine		
American Academy of Addiction Psychiatry		
American Medical Association		
American Osteopathic Association		
American Psychiatric Association Other (Specify, include date and location)		
Participation as an investigator in one or more clinical trials leading to the approval of a Schedule III, IV, or V narcotic drug for maintenance or detoxification treatment		
State medical licensing board-approved experience or training in the treatment and management of opioid-dependent patients		
OTHER (Specify)		
9. CERTIFICATION OF CAPACITY		
I certify that I have the capacity to refer patients for appropriate counseling and other appropriate ancillary services.		

SMA-167 Page 2

10. CERTIFICATION OF MAXIMUM PATIENT LOAD		
I certify that I will not exceed 30 patients for maintenance or detoxification treatment at one time.		
11. CONSENT TO RELEASE IDENTIFYING INFORMATION TO SAMHSA BUPRENORPHINE PHYSICIAN LOCATOR WEB SITE (Read instruction 11 below before answering)		
I consent to the release of my name, primary address, and phone number to the SAMHSA Buprenorphine Physician Locator Web site.		
I do not consent to the release of my name, primary address, and phone number to the SAMHSA Buprenorphine Physician Locator Web site.		
12. I certify that the information presented above is true and correct to the best of my knowledge. I certify that I will notify SAMHSA at the address below if any of the information contained on this form changes. Note: Any false, fictitious, or fraudulent statements or information presented above or misrepresentations relative thereto may violate Federal laws and could subject you to prosecution, and/or monetary penalties, and or denial, revocation, or suspension of DEA registration. (See 18 USC § 1001; 31 USC §§ 3801–3812; 21 USC § 824.)		
Signature	Date	
	Please send the completed form to: Substance Abuse and Mental Hee Division of Pharmacologic Theral Attention: Opioid Treatment Wa One Choke Cherry Road, Rm 2-1 Rockville, MD 20857 Fax 240-276-1630 Phone 1-866-287-2728 (1-866-BU	oies iver Program 063
This form is intended to facilitate the implementation of the provisions of 21 USC § 823(g)(2). The Secretary of DHHS will use the information provided to determine whether practitioners meet the qualifications for waivers from the separate registration requirements under the Controlled Substances Act (21 USC § 823(g)(1)). The Drug Enforcement Administration will assign an identification number to qualifying practitioners and the number will be included in the practitioner's registration under 21 USC § 823(f). This form may be completed and submitted electronically (including facsimile) to facilitate processing.		
This form may be completed and submitted electronically (including lacistimic) to lacindate processing.		
1. The practitioner must identify the DEA registration numb prescribe substances controlled in Schedules III, IV, or V.	er issued under 21 USC § 823(f) to	2. Only one address should be specified. For the practitioner to dispense the narcotic drugs or combinations to be used under this notification, the primary address listed here must be the same primary address listed in the practitioner's registration under § 823(f).
6. Purpose of notification:		
New Notification - an initial notification for a waiver submitted for the purpose of obtaining an identification number from DEA for inclusion in the registration under 21 USC § 823(f).		
New Notification, with the intent to immediately facilitate treatment of an individual (one) patient - an initial notification submitted for the purpose described above, with the additional purpose of notifying the Secretary and the Attorney General of the intent to provide immediate opiate addiction treatment for an individual (one) patient pending processing of this waiver notification.		
11. The SAMHSA Buprenorphine Physician Locator Web site is publicly accessible at http://buprenorphine.samhsa.gov/bwns_locator/ . The Locator Web site lists the names and practice contact information of physicians with DATA waivers who agree to be listed on the site. The Locator Web site is used by the treatment-seeking public and health care professionals to find physicians with DATA waivers. The Locator Web site additionally provides links to many other sources of information on substance abuse. No physician listings on the SAMHSA Buprenorphine Physician Locator Web site will be made without the express consent of the physician.		
PRIVACY ACT INFORMATION		
Authority: Section 303 of the Controlled Substances Act of 1970 (21 USC § 823(g)(2)). Purpose: To obtain information required to determine whether a practitioner meets the requirements of 21 USC § 823(g)(2). Routine Uses: Disclosures of information from this system are made to the following categories of users for the purposes stated: A. Medical specialty societies to verify practitioner qualifications. B. Other federal law enforcement and regulatory agencies for law enforcement and regulatory purposes. C. State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes. D. Persons registered under the Controlled Substance Act (PL 91-513) for the purpose of verifying the registration of customers and practitioners.		
Effect: This form was created to facilitate the submission and review of waivers under 21 USC § 823(g)(2). This does not preclude other forms of notification.		
Paperwork Reduction Act Statement		
Public reporting burden for completing this form is estimated to average 4 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the completed form. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0930-0234. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to SAMHSA Reports Clearance Officer; Paperwork Reduction Project (0930-0234); Room 71-1044, One Choke Cherry Road, Rockville, MD 20857		